ONCTERNAL THERAPEUTICS INC (ONCT)

US68236P2065 - Common Stock

0.71  -0.43 (-37.72%)

After market: 0.73 +0.02 (+2.82%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ONCTERNAL THERAPEUTICS INC

NASDAQ:ONCT (11/25/2024, 4:05:51 PM)

After market: 0.73 +0.02 (+2.82%)

0.71

-0.43 (-37.72%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-87.62%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap2.10M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ONCT Daily chart

Company Profile

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 27 full-time employees. The company went IPO on 2004-02-03. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

Company Info

ONCTERNAL THERAPEUTICS INC

12230 El Camino Real, Suite 230

San Diego CALIFORNIA 92130

P: 18584341113

CEO: James B. Breitmeyer

Employees: 29

Website: https://www.oncternal.com/

ONCT News

ChartMill News Imagean hour ago - ChartmillLet's take a look at the stocks that are in motion in today's session.

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

ChartMill News Image4 hours ago - ChartmillLet's take a look at the stocks that are in motion in today's session.

Top movers analysis in the middle of the day on 2024-11-25: top gainers and losers in today's session.

ChartMill News Image6 hours ago - ChartmillThe market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.

Which stocks are gapping on Monday?

ChartMill News Image8 hours ago - ChartmillWhich stocks are moving before the opening bell on Monday?

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

News Imagea month ago - Oncternal TherapeuticsOncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced updated data from its Phase 1/2...

News Image2 months ago - Oncternal TherapeuticsOncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced its decision to discontinue its...

ONCT Twits

Here you can normally see the latest stock twits on ONCT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example